MedTrace Logo

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT06667960 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2026-03-05

No results posted yet for this study

Summary

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.

Conditions

Interventions

DRUG

JK06

Biparatopic anti-5T4 antibody

Sponsors & Collaborators

  • Salubris Biotherapeutics Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-23
Primary Completion
2028-04-01
Completion
2028-08-01

Countries

  • Belgium
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667960 on ClinicalTrials.gov